干扰素α治疗丙型肝炎对甲状腺功能的影响

Alteration of thyroid function in chronic hepatitis C treated with interferon-α

目的研究干扰素α对慢性丙型病毒性肝炎(CHC)患者甲状腺功能的影响。方法随机收集97例CHC患者,观察使用干扰素后出现甲状腺功能异常情况、干扰素抗病毒治疗基线值及第4、12、24、36、48、72周的甲状腺功能等。结果 97例CHC患者干扰素治疗后共11例出现甲状腺功能异常,其中甲减8例,甲亢3例,甲功异常发生率为11.34%,以甲减更常见。CHC患者使用大剂量和小剂量干扰素治疗各时间段出现甲状腺功能异常率差异无统计学意义。结论干扰素治疗CHC患者出现甲减比甲亢更常见,但不能证明大剂量聚乙二醇干扰素α(PEG-IFNα)更容易导致甲状腺功能异常。

Objective To find out the impact of interferon-α on thyroid function in the treatment of chronic hepatitis C （CHC）. Methods 97 patients with CI-IC were included in our study. During this 72-week period, thyroid function of the patients were evaluated at week 0,4,12,24,36,48 and 72. Results Among the 97 CHC patients, 11（11.34%） of them had abnormal thyroid function after interferon therapy. Overall we found 8 patients with hypothyroidism and 3 with hyperthyroidism. Thyroid abnormality rates had no significant difference between large dose group and small dose group. Conclusion In the interferon therapy, patients with CHC were more prone to hypothyroidism.